From the Guidelines
Lyumjev is a rapid-acting insulin analog (insulin lispro-aabc) injection used to control high blood sugar in adults with diabetes mellitus, with a faster onset of action compared to traditional rapid-acting insulins, as noted in the 2022 standards of medical care in diabetes 1.
Key Characteristics of Lyumjev
- Works faster than traditional rapid-acting insulins, beginning to lower blood glucose within approximately 15 minutes after injection
- Typically administered subcutaneously within 20 minutes before or immediately after starting a meal
- Can be used in insulin pumps
- Dosage is individualized based on the patient's blood glucose levels, with adjustments made according to medical supervision
- Contains additional ingredients that enhance its absorption speed compared to other rapid insulins
Clinical Considerations
- May cause hypoglycemia, and patients should monitor blood glucose levels regularly
- Should be stored properly (refrigerated before opening, then at room temperature for up to 28 days) and inspected for clarity before each use, as cloudy or discolored insulin should not be used
- Part of a larger strategy for managing diabetes, which may include basal insulin, mealtime insulin, and correction insulin, as outlined in the 2022 standards of medical care in diabetes 1
Evidence-Based Recommendations
- The use of rapid-acting insulin analogs like Lyumjev is supported by recent guidelines, which highlight their potential to reduce hypoglycemia and improve glycemic control in patients with type 1 diabetes 1
- Individualized treatment plans, taking into account factors like patient preferences, cost, and self-management capabilities, are essential for optimizing outcomes with Lyumjev and other insulin therapies 1
From the FDA Drug Label
LYUMJEV is a man-made fast-acting insulin used to control high blood sugar in adults and children with diabetes mellitus. Insulin lispro-aabc is a rapid-acting human insulin analog used to lower blood glucose.
Lyumjev Injection is a man-made, fast-acting insulin used to control high blood sugar in adults and children with diabetes mellitus. It is a rapid-acting human insulin analog used to lower blood glucose. Key points about Lyumjev injection include:
- It is used for subcutaneous or intravenous administration
- It comes in two strengths: U-100 (100 units/mL) and U-200 (200 units/mL)
- LYUMJEV U-200 contains 2 times as much insulin as LYUMJEV U-100 2 2
From the Research
Overview of Lyumjev Injection
- Lyumjev, also known as insulin lispro-aabc, is a rapid-acting insulin analogue used for the treatment of diabetes mellitus 3.
- It is designed to improve postprandial glucose control and has a faster onset of action compared to regular human insulin 4.
Mechanism of Action
- Insulin lispro, the active ingredient in Lyumjev, has a more rapid absorption and shorter duration of action compared to regular human insulin, allowing for injection closer to mealtime 5.
- This results in lower postprandial glucose levels and a reduced risk of hypoglycemia 4.
Clinical Studies
- A study comparing Lyumjev to Humalog in individuals with type 1 diabetes on continuous subcutaneous insulin infusion found that Lyumjev shortened the time to recovery from hyperglycemia 3.
- Another study found that insulin lispro mixtures, which include Lyumjev, maintained rapid activity and allowed for injection just prior to a meal, resulting in a smaller increase in blood glucose levels after meals 6.
- A double-blind crossover study found that insulin lispro improved glycemic control in continuous subcutaneous insulin infusion without increasing the risk of hypoglycemia 7.